Question 1: Metronidazole is listed by the International Agency for Research on Cancer (IARC) as a potential human ________. | |||
|
Question 2: ________ administered early in the second trimester to women who test positive for bacterial vaginosis seems to be more effective. | |||
|
Question 3: How is Metronidazole excreted?
|
|||
|
Question 4: Metronidazole is banned in the ________ for veterinary use in the feed of animals. | |||
|
Question 5: What is the chemical name of Metronidazole (IUPAC)
|
|||
|
Question 6: ________, commonly associated with overgrowth of Gardnerella species and coinfective anaerobes (Mobiluncus, Bacteroides), in symptomatic patients | |||
|
Question 7: Topical metronidazole is indicated for the treatment of ________, and in the treatment of malodorous fungating wounds. | |||
|
Question 8: Metronidazole has also been used in women to prevent preterm birth associated with ________, amongst other risk factors including the presence of cervicovaginal fetal fibronectin (fFN). | |||
|
Question 9: Metronidazole alone rarely causes ________ but is reported to occur at high rates when combined with Mebendazole. | |||
|
Question 10: Vaginitis due to ________ infection[2] in both symptomatic patients as well as their asymptomatic sexual contacts - always consult the GP and contact all previous partners | |||
|
|